- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
Novo Nordisk A/S Annual Shareholders Meeting Transcript
/-
Good afternoon. On behalf of the Board, welcome to Novo Nordisk Annual General Meeting 2024. I am Helge Lund, and I am the Chair of the Board of Directors. It gives me great pleasure to open this year's Annual General Meeting. And looking back at 2023, it has been indeed an exceptional year of innovation, our growth and also value creation and impact for the company. We will report on the progress later in the meeting. For those of you who prefer Danish or English, simultaneous translation is available here in the Bella Center and online participants can choose to the preferred language in the broadcast system.
As we reflect on the year that's passed, it has become clear that as our business continues to grow, so does our role in society. And big companies have big responsibilities. The global burden of serious chronic diseases poses a significant threat to global health, and we recognize that innovative and sustainable solutions are needed to address these challenges. Our industry-leading therapeutic
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |